Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model
碩士 === 長庚大學 === 生物醫學研究所 === 99 === Cervical cancer is the second largest cause of cancer-related death in women Worldwide, which occurs following persistent infection with specific high-risk human papillomaviruses (HPV). Even though the prophylactic vaccines were approved and became available in the...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Published: |
2011
|
Online Access: | http://ndltd.ncl.edu.tw/handle/18839765932401606662 |
id |
ndltd-TW-099CGU05114010 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-099CGU051140102015-10-19T04:03:40Z http://ndltd.ncl.edu.tw/handle/18839765932401606662 Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model 由GMCSF高分泌能力的TC-1腫瘤細胞製成的疫苗對小鼠模組造成的T淋巴細胞與樹突細胞免疫反應研究 Guo Shiang Jang 張國祥 碩士 長庚大學 生物醫學研究所 99 Cervical cancer is the second largest cause of cancer-related death in women Worldwide, which occurs following persistent infection with specific high-risk human papillomaviruses (HPV). Even though the prophylactic vaccines were approved and became available in the market in recent years. There also need therapeutic vaccines to combat high-risk HPV-associated cancers of those had been infected. In order to increase tumor antigen presentation of therapeutic vaccines, we previously modified wild-type GM-CSF gene (wtGM) into codon-optimized GM-CSF (cGM), and then used lentivirus as a vector to deliver GM-CSF gene into a HPV-16 E6/E7 transformed cell line, TC-1. It was verified that TC-1/cGM cells significantly increased steady-state mRNA levels of GM-CSF and further enhanced GM-CSF protein expression. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an important hematopoietic growth factor and has profound effects on the functional activities of various leukocytes including T-cells and dendritic cells. In this study, the mice were inoculated with irradiated TC-1/cGM cell-based vaccine, and evaluated its effects on antigen-specific T-cell and dendritic cells (DCs) proliferation and activation by flow cytometric analysis. The antitumor immunity in vivo was monitored using a non-invasive animal position-emission tomography (microPET) imaging. It showed that mice vaccinated with TC-1 or TC-1/wtGM increased a lower level of CD8+ T-cells and DCs immune response. However, administration of TC-1/cGM vaccine revealed more potent immunity to elicit anti-tumor efficacy. J. T. Qiu 邱健泰 2011 學位論文 ; thesis 66 |
collection |
NDLTD |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 長庚大學 === 生物醫學研究所 === 99 === Cervical cancer is the second largest cause of cancer-related death in women Worldwide, which occurs following persistent infection with specific high-risk human papillomaviruses (HPV). Even though the prophylactic vaccines were approved and became available in the market in recent years. There also need therapeutic vaccines to combat high-risk HPV-associated cancers of those had been infected. In order to increase tumor antigen presentation of therapeutic vaccines, we previously modified wild-type GM-CSF gene (wtGM) into codon-optimized GM-CSF (cGM), and then used lentivirus as a vector to deliver GM-CSF gene into a HPV-16 E6/E7 transformed cell line, TC-1. It was verified that TC-1/cGM cells significantly increased steady-state mRNA levels of GM-CSF and further enhanced GM-CSF protein expression. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is an important hematopoietic growth factor and has profound effects on the functional activities of various leukocytes including T-cells and dendritic cells. In this study, the mice were inoculated with irradiated TC-1/cGM cell-based vaccine, and evaluated its effects on antigen-specific T-cell and dendritic cells (DCs) proliferation and activation by flow cytometric analysis. The antitumor immunity in vivo was monitored using a non-invasive animal position-emission tomography (microPET) imaging. It showed that mice vaccinated with TC-1 or TC-1/wtGM increased a lower level of CD8+ T-cells and DCs immune response. However, administration of TC-1/cGM vaccine revealed more potent immunity to elicit anti-tumor efficacy.
|
author2 |
J. T. Qiu |
author_facet |
J. T. Qiu Guo Shiang Jang 張國祥 |
author |
Guo Shiang Jang 張國祥 |
spellingShingle |
Guo Shiang Jang 張國祥 Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
author_sort |
Guo Shiang Jang |
title |
Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
title_short |
Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
title_full |
Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
title_fullStr |
Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
title_full_unstemmed |
Study the immune responses of both T lymphocytes and dendritic cells to a high-dose GM-CSF-secreting cell-based vaccine in murine TC-1 cancer model |
title_sort |
study the immune responses of both t lymphocytes and dendritic cells to a high-dose gm-csf-secreting cell-based vaccine in murine tc-1 cancer model |
publishDate |
2011 |
url |
http://ndltd.ncl.edu.tw/handle/18839765932401606662 |
work_keys_str_mv |
AT guoshiangjang studytheimmuneresponsesofbothtlymphocytesanddendriticcellstoahighdosegmcsfsecretingcellbasedvaccineinmurinetc1cancermodel AT zhāngguóxiáng studytheimmuneresponsesofbothtlymphocytesanddendriticcellstoahighdosegmcsfsecretingcellbasedvaccineinmurinetc1cancermodel AT guoshiangjang yóugmcsfgāofēnmìnénglìdetc1zhǒngliúxìbāozhìchéngdeyìmiáoduìxiǎoshǔmózǔzàochéngdetlínbāxìbāoyǔshùtūxìbāomiǎnyìfǎnyīngyánjiū AT zhāngguóxiáng yóugmcsfgāofēnmìnénglìdetc1zhǒngliúxìbāozhìchéngdeyìmiáoduìxiǎoshǔmózǔzàochéngdetlínbāxìbāoyǔshùtūxìbāomiǎnyìfǎnyīngyánjiū |
_version_ |
1718093646063992832 |